EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Patient- and Clinician-Reported Meaningfulness of Treatment-Related Change Following Investigational Sirolimus Topical Gel 3.9% in Microcystic Lymphatic Malformations: Qualitative Findings From the Phase 3 SELVA Trial Show Clinical Benefit and High Treatment Satisfaction

Maria Gnarra Beuthe, Kristen Kahle, James Treat, Denise Adams, Sally Cohen-Cutler, Michael Kelly, Megha Tollefson, Amy Theos, Jeffrey Martini, Wes Kaupinen, Emily Cook, Andrea Zaenglein, Kiersten Ricci, Elizabeth Nieman, Ionela Iacobas, Michael White, Neeraja Swaminathan, Stacie Hudgens, Joyce Teng

SKIN The Journal of Cutaneous Medicine · 2026-11-10 · 10 (6) · s823

DOI: 10.25251/3ggsk832 ↗
AbstractBibliografische Angaben

Abstract

Introduction: Microcystic lymphatic malformations (mLM) are lifelong, rare, and serious vascular anomalies associated with substantial physical and psychosocial morbidity. Currently, no FDA-approved therapeutics exist; disease management involves invasive procedures (surgery, sclerotherapy, laser) and off-label oral and topical sirolimus, all associated with inconsistent results. Sirolimus topical gel 3.9%, developed on the QTORIN™ platform to address these unmet therapeutic needs, was evaluated in the pivotal Phase 3 SELVA trial. Consistent with regulatory guidance emphasizing the patient voice in drug development, an embedded qualitative interview study characterized patient/caregiver perspectives of mLM and the meaningfulness of treatment-related change. Objective: To contextualize clinical trial efficacy endpoints through the patient/caregiver experience and evaluate treatment satisfaction following topical sirolimus 3.9% gel. Methods: Semi-structured entry (baseline) and exit (Day 168) interviews were conducted with trial participants and/or their caregivers (for participants

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →